Forest Laboratories
- Company typePrivate
- Founded1954
- HeadquartersNew York, United States
- Headcount1,001–5,000
- GTM typeB2B
- OfferingHardware or Manufacturing
Forest Laboratories firmographics
Firmographics- Name
- Forest Laboratories
- Legal name
- Forest Laboratories, LLC
- Website
- https://frx.com
- Company type
- Private
- Founded year
- 1954
- Operating status
- Acquired
- Headcount range
- 1,001–5,000 employees
- Ownership category
- akta.pro rank
Forest Laboratories industry classification
Industry- Product category
- Pharmaceuticals
- NAICS
- Pharmaceutical Preparation Manufacturing (325412)
- SIC
- Pharmaceutical Preparations (2834)
- akta.pro primary industry
- Neurology & Psychiatry (CNS) Pharmaceuticals (HLAIAAAF)
- akta.pro secondary industry
- Neurology & CNS Specialty Pharmaceuticals (HLAIACAC)
Keywords
Where Forest Laboratories is headquartered
LocationHeadquarters
- HQ city
- New York
- HQ country
- United States
- HQ region
- North America
Markets served
Forest Laboratories business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Personnel, Technology or R&D, Operations, Marketing or Sales, Supply Chain
Forest Laboratories product offering
Product offeringCore offering
Forest Laboratories fundamentally developed, manufactured, and marketed branded pharmaceutical products, with historical emphasis on treatments for central nervous system (CNS) conditions and learning disabilities. Its commercial activities centered on prescription medications marketed to healthcare providers and patients, supported by an acquisition-driven growth strategy that expanded its therapeutic portfolio across multiple disease areas.
Differentiator
Problem solved
Functional benefit
Products and services
- Learning Disabilities Treatment Pharmaceuticals Branded pharmaceutical products developed and marketed for the treatment of learning disabilities and related CNS conditions, targeted to healthcare providers and patients.
Companies that use Forest Laboratories
Customer profileSegments1 record
Ideal customer profiles1 record
Forest Laboratories technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Forest Laboratories partnerships and signals
Strategic signalScale indicators2 records
Recent moves7 records
Expansion highlights4 records
Forest Laboratories competitors and assessment
Company assessmentBroad incumbents
- Pfizer: Pfizer is a large branded innovator pharmaceutical company with historic CNS and neurology exposure (e.g., legacy neuropathic pain, CNS franchises). Comparable as a broad-incumbent pharma with adjacent CNS therapeutic reach and similar scale dynamics.
- AbbVie: AbbVie is the current ultimate parent of Forest Laboratories following the 2020 acquisition of Allergan. AbbVie's $63 billion Allergan deal absorbed Forest and now controls its CNS franchise as part of a portfolio spanning 30+ brands and 60+ therapeutic conditions.
- Allergan (legacy): Allergan acquired Forest Laboratories in 2014 for approximately $25 billion and operated it as a subsidiary until AbbVie's 2020 acquisition. Allergan's diversified specialty pharma portfolio offered overlapping CNS and broader therapeutic capabilities during its ownership of Forest.
- GlaxoSmithKline: GSK is a large branded pharmaceutical company with CNS and neurology product lines. Comparable as a broad-incumbent pharma with branded small-molecule drug development, commercialization, and regulatory expertise across overlapping therapeutic categories.
- Novartis: Novartis is a large branded innovator pharmaceutical company with neurology and CNS therapeutic areas (e.g., multiple sclerosis, neurology). Comparable as a broad-incumbent pharma with overlapping R&D and commercialization capabilities in CNS-adjacent indications.
Direct peers
- Jazz Pharmaceuticals: Jazz Pharmaceuticals is a specialty pharma company with material CNS exposure (e.g., neuroscience franchise for narcolepsy, epilepsy, and other CNS disorders). Comparable as a focused specialty pharma peer competing in CNS-adjacent therapeutic areas.
- Lundbeck: Lundbeck is a specialty pharmaceutical company focused exclusively on CNS and brain diseases — its portfolio includes treatments for depression, anxiety, Alzheimer's, Parkinson's, and other neurological disorders that overlap directly with Forest's CNS specialty focus.
- Eli Lilly and Company: Eli Lilly is explicitly named as a key competitor alongside Forest Laboratories in the global Learning Disabilities Treatment market. Both companies operate in branded CNS pharmaceuticals with overlapping therapeutic areas including neurology and psychiatry.
- Takeda Pharmaceutical Company: Takeda is explicitly named as a key competitor of Forest Laboratories in the global Learning Disabilities Treatment market. Both companies participate in branded CNS pharmaceutical development with comparable target patient populations and regulatory pathways.
Emerging players
- CogniFit: CogniFit is explicitly named as a key industry player alongside Forest Laboratories in the global Learning Disabilities Treatment market. As an emerging player, CogniFit addresses learning disabilities through cognitive training software rather than pharmaceuticals, offering an adjacent rather than directly competing modality.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat4 records
Key risks5 records
Key highlights5 records
Customer concentration
Forest Laboratories social profiles
Digital presenceForest Laboratories financial estimates
Financial estimateRevenue estimate
Valuation estimate
Forest Laboratories leadership team
Management profileNumber of profiles
Forest Laboratories funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Forest Laboratories M&A and investment
M&A and investmentM&A4 records
Investments3 records
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Forest Laboratories
What does Forest Laboratories do?
Forest Laboratories fundamentally developed, manufactured, and marketed branded pharmaceutical products, with historical emphasis on treatments for central nervous system (CNS) conditions and learning disabilities. Its commercial activities centered on prescription medications marketed to healthcare providers and patients, supported by an acquisition-driven growth strategy that expanded its therapeutic portfolio across multiple disease areas.
Is Forest Laboratories a public or private company?
Forest Laboratories is a private company. It is classified as corporate owned and is currently acquired.
When was Forest Laboratories founded?
Forest Laboratories was founded in 1954. It employs 1,001 to 5,000 people.
Where is Forest Laboratories based?
Forest Laboratories is headquartered in New York, United States, in the North America region.
Who are Forest Laboratories's main competitors?
Broad incumbents on record are Pfizer, AbbVie, Allergan (legacy), GlaxoSmithKline and Novartis. Direct peers are Jazz Pharmaceuticals, Lundbeck, Eli Lilly and Company and Takeda Pharmaceutical Company. CogniFit is listed as an emerging player.
Does Forest Laboratories have an API?
No public API is recorded for Forest Laboratories.
What industry is Forest Laboratories in?
Forest Laboratories's product category is Pharmaceuticals. Its primary akta.pro industry code is HLAIAAAF, Neurology & Psychiatry (CNS) Pharmaceuticals, with a secondary code of HLAIACAC, Neurology & CNS Specialty Pharmaceuticals. Its NAICS code is 325412 and its SIC code is 2834.